Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway

Area of Science:

• Cardiovascular Research
• Metabolic Disease Research
• Molecular Biology

Background:

• Fenofibrate, a PPARα agonist, reduces cardiovascular events in type 2 diabetes.
• Hindlimb ischemia is a condition characterized by impaired blood flow to the limbs.
• Understanding mechanisms that promote vascular repair is crucial for treating ischemic diseases.

Purpose of the Study:

• To investigate the effect of fenofibrate on revascularization in a mouse model of hindlimb ischemia.
• To elucidate the molecular pathways, including adiponectin, AMPK, and eNOS, involved in fenofibrate-mediated revascularization.

Main Methods:

• Treatment of wild-type (WT) and adiponectin-deficient (APN-KO) mice with fenofibrate.
• Assessment of revascularization using laser Doppler blood flow and capillary density.
• Analysis of protein phosphorylation (AMPK, eNOS) and inhibition studies with Compound C and l-NAME.

Main Results:

• Fenofibrate treatment accelerated revascularization in WT mice, evidenced by increased blood flow and capillary density.
• Fenofibrate increased serum adiponectin levels in WT mice.
• Fenofibrate's pro-revascularization effects were abolished in APN-KO mice.
• Fenofibrate-induced revascularization involved the activation of AMPK and eNOS, which was dependent on adiponectin.

Conclusions:

• Fenofibrate promotes revascularization of ischemic hindlimbs.
• The mechanism involves an increase in adiponectin, leading to the activation of AMPK and eNOS signaling.
• Fenofibrate may represent a therapeutic strategy to enhance vascular repair in ischemic conditions.